Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time.

Erica A PowerJulian S RechbergerLiang ZhangJu-Hee OhJacob B AndersonCody L NesvickJizhi GeEdward H HinchcliffeWilliam F ElmquistDavid J Daniels

Published in: Neuro-oncology advances (2023)

These studies provide evidence for increasing drug-tumor residence time of promising targeted therapies via extended CED as a valuable treatment strategy for DMG.

Keyphrases

low grade
adverse drug
drug induced
case control